Medical Philosophy
Regenerative medicine produces results only when the biology of the disease is understood before treatment begins. At BioCells Medical, every programme starts with molecular and immunological profiling, as well as analysis of the disease trajectory — before any therapeutic decision is made.
Cellular therapy is treated not as a procedure but as a precise medical intervention. The outcome is determined by the quality of preparation: how cells are produced and tested, how the protocol is structured, and how systematic the post-treatment monitoring is.
Methodology
Every programme rests on three mandatory principles. Violation of any one of them makes the clinical outcome unpredictable.
The protocol is built from the patient's specific clinical and laboratory data, not from the diagnosis alone
Full molecular and immunological profiling precedes every decision
Cell type, dosage, route of administration, and sequencing are determined by immune status, the severity of neuroinflammation, and the stage and rate of disease progression
The protocol is approved by the multidisciplinary medical board and adjusted over time based on biomarkers and clinical response
The entire chain — from biological material collection to administration to the patient — is under direct laboratory oversight
Every cell batch undergoes cultivation, as well as mandatory verification of viability, sterility, and functional activity before use
All therapeutic components of the programme — mesenchymal stem cells (MSCs), T-regulatory cells, exosomes, as well as accompanying biological products — are prepared individually for the patient
Full traceability, including processing stages and storage conditions, is documented in accordance with EU regulatory requirements
Clinical scales and biomarkers — objective assessment instead of subjective impressions
Validated assessment instruments for every diagnosis: ALSFRS-R for ALS, EDSS for multiple sclerosis, UPDRS for Parkinson's disease, GMFCS/GMFM for cerebral palsy, and others
Biomarker assessment before therapy starts, during treatment, and throughout the long-term follow-up period
Wearable monitoring devices for continuous objective collection of physiological and functional data between clinic visits
Clinical registry with more than 2,500 longitudinal patient observations, systematically maintained since 2013
Context
The regenerative medicine market includes clinics operating under very different standards. These are the specific differences patients and referring physicians should be aware of.
Common Industry Practice
BioCells Medical
Standardised protocol applied to all patients with the same diagnosis
Protocol built on the basis of individual molecular and immune profiling, taking into account the clinical dynamics and biological characteristics of the patient
Cells sourced from external suppliers or commercial tissue banks
All therapeutic components are produced in-house in a certified cell laboratory in Warsaw under direct laboratory oversight
Cells often administered without laboratory expansion — protocol and bone marrow collection completed within a few days
Full laboratory preparation with cultivation (14–21 days) and quality control (viability, sterility, functional activity); the complete cycle from sample collection to administration takes approximately one month
No batch documentation or cell passport released to the patient — biological product without a documented identity
Every cell batch is released with a cell passport: quality parameters, processing and storage conditions, and complete traceability in accordance with the EU regulatory framework
Limited or no structured follow-up after discharge
Structured long-term monitoring programme with clinical scales, biomarkers, remote follow-up, and individualised rehabilitation
Outcomes described in general, promotional terms
Results are measured using validated clinical scales and presented with objective data and documented clinical limitations
Facilities operating outside EU regulatory oversight
Warsaw-based clinic operating within European medical requirements with full traceability across all stages of treatment
Common Industry Practice
Standardised protocol applied to all patients with the same diagnosis
BioCells Medical
Protocol built on the basis of individual molecular and immune profiling, taking into account the clinical dynamics and biological characteristics of the patient
Common Industry Practice
Cells sourced from external suppliers or commercial tissue banks
BioCells Medical
All therapeutic components are produced in-house in a certified cell laboratory in Warsaw under direct laboratory oversight
Common Industry Practice
Cells often administered without laboratory expansion — protocol and bone marrow collection completed within a few days
BioCells Medical
Full laboratory preparation with cultivation (14–21 days) and quality control (viability, sterility, functional activity); the complete cycle from sample collection to administration takes approximately one month
Common Industry Practice
No batch documentation or cell passport released to the patient — biological product without a documented identity
BioCells Medical
Every cell batch is released with a cell passport: quality parameters, processing and storage conditions, and complete traceability in accordance with the EU regulatory framework
Common Industry Practice
Limited or no structured follow-up after discharge
BioCells Medical
Structured long-term monitoring programme with clinical scales, biomarkers, remote follow-up, and individualised rehabilitation
Common Industry Practice
Outcomes described in general, promotional terms
BioCells Medical
Results are measured using validated clinical scales and presented with objective data and documented clinical limitations
Common Industry Practice
Facilities operating outside EU regulatory oversight
BioCells Medical
Warsaw-based clinic operating within European medical requirements with full traceability across all stages of treatment
Each programme is designed for functional stabilisation, slowing disease progression, and documented improvement in quality of life on the basis of objective clinical data. Confidential medical consultations — no obligation.
